On August 6, 2024, SciSparc announced promising results from a new study on 5-methoxy-2-aminoindane (MEAI), conducted in collaboration with Clearmind Medicine. The research, led by Prof. Joseph Tam at the Hebrew University of Jerusalem, demonstrated significant weight loss effects in diet-induced obese mice, with notable reductions in fat mass while preserving lean mass.The study revealed improvements in glucose metabolism, increased energy expenditure, and enhanced fat utilization. Key findings included decreased fatty liver conditions, lower liver triglyceride and cholesterol levels, and reduced fat accumulation. The treatment was well-tolerated and showed increased metabolic processes without affecting food consumption.Since 2022, SciSparc and Clearmind have been collaborating to develop innovative treatments for obesity and metabolic syndrome, combining SciSparc's Palmitoylethanolamide (PEA) with Clearmind's MEAI. Their partnership has resulted in multiple patent applications, leveraging Clearmind's psychedelic-derived therapeutics expertise and SciSparc's cannabinoid-based pharmaceutical innovations.

On August 6, 2024, SciSparc announced promising results from a new study on 5-methoxy-2-aminoindane (MEAI), conducted in collaboration with Clearmind Medicine. The research, led by Prof. Joseph Tam at the Hebrew University of Jerusalem, demonstrated significant weight loss effects in diet-induced obese mice, with notable reductions in fat mass while preserving lean mass.The study revealed improvements in glucose metabolism, increased energy expenditure, and enhanced fat utilization. Key findings included decreased fatty liver conditions, lower liver triglyceride and cholesterol levels, and reduced fat accumulation. The treatment was well-tolerated and showed increased metabolic processes without affecting food consumption.Since 2022, SciSparc and Clearmind have been collaborating to develop innovative treatments for obesity and metabolic syndrome, combining SciSparc's Palmitoylethanolamide (PEA) with Clearmind's MEAI. Their partnership has resulted in multiple patent applications, leveraging Clearmind's psychedelic-derived therapeutics expertise and SciSparc's cannabinoid-based pharmaceutical innovations.